about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesSingle cell analysis of drug distribution by intravital imagingInvestigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometryFunction of BRCA1 in the DNA damage response is mediated by ADP-ribosylationRegulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposureFailure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroEmerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disordersFunctions of PARylation in DNA Damage Repair PathwaysCurrent and emerging therapies in unresectable and recurrent gastric cancerNew treatment option for ovarian cancer: PARP inhibitorsTrial watch - inhibiting PARP enzymes for anticancer therapyRadioresistance of Brain TumorsMolecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic CancerPARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future PerspectivesDNA repair targeted therapy: The past or future of cancer treatment?DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerSuccesses and Challenges of PARP Inhibitors in Cancer TherapyChemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative MedicineOlaparib in the management of ovarian cancerPoly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and TumorogenesisRepair of oxidative DNA damage and cancer: recent progress in DNA base excision repairImproving the efficacy of chemoradiation with targeted agentsNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsPleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammationPARPs and the DNA damage responseThe role of PARP in DNA repair and its therapeutic exploitationAdvances in using PARP inhibitors to treat cancerStructure and function of the ARH family of ADP-ribosyl-acceptor hydrolasesDNA Damage and Pulmonary HypertensionThe role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapyTargeting DNA damage response in cancer therapyPARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier.Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewPARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions.Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA: STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY
P2860
Q21129302-5A9B297B-B5BD-4BF7-88D6-4BBE50A6FCABQ21133568-40236392-E0CE-42E6-A97B-5688C971BBA6Q21245636-3436D5EF-B90E-418F-9002-9EEEFF1121A2Q24293084-E814402C-0F68-4461-8B05-4ED62591608EQ24294656-74AA5778-4E13-420A-B405-FB8E3308D11FQ24595686-7DC222C9-0811-4B17-A7AE-4703B15A57AFQ24615499-19FB469A-212C-4D86-BD4D-C166DB0C2111Q26741300-1A741FE5-00FA-431F-9BC0-F16114285E1BQ26744796-55ABA308-178F-4BDF-A6C0-ABC2D3618CD7Q26745453-3B0E715C-8D6B-4501-A070-447FA53DBE7FQ26745614-B6FCE8CB-7927-462B-8D0E-536D669749C6Q26745673-E774B44F-43D0-4A0C-87CD-D0591B77F08EQ26752579-19F16159-3B1D-4B86-BE00-C0F1509C0C68Q26765241-57AD6AAE-2FBC-4A1A-9980-B424844296B7Q26768661-5D5516CD-5BF2-46CD-A7CC-7F0D1D5F358FQ26768679-26853E7A-F82E-4483-BF11-76BA8F7DA577Q26776513-2C83A4E5-2589-4E4A-8672-DAF93DD8CC6DQ26777131-671DEE14-0C83-4FEF-BB68-7B71915D29CEQ26796673-F3749A86-2D8C-4E06-8B40-C2D3CBBD69E8Q26797166-B95ABAA5-3AD4-4EB0-8C90-99DC29B753DCQ26800013-01AE769A-F981-4679-96DF-225709D81BA4Q26822957-E57C680E-0EC0-4C6E-B474-98A6855E40C1Q26850193-008A1811-B9FF-4FE8-9E44-DB3FAFFFF2D8Q26851765-B3D102DE-BF11-463A-A520-28FDF00E20E2Q26852274-310568C7-A099-4D23-9FE5-0A03DCC3A2EDQ26858894-A8BA8905-F13A-47C1-B476-EAF5A913FC46Q26859010-67ABC619-A7A5-4456-8D74-02CC717F962BQ27002399-C8BF8A44-B6F7-471E-ABA3-6DD80A11695CQ27003972-716F1927-F312-4838-8CFA-DFB5C6A78AEFQ27004584-625C7723-B9F7-40E5-925F-30F21F67B28FQ27005594-A733C35E-A73A-48A2-8725-0A2FFF57C2A5Q27010084-4B8196C5-4545-4978-B404-1B7CD1C6447BQ27023204-68FB4AFF-B67D-44BE-A172-786913F16B88Q27303034-B5E9D435-1A0B-4069-837D-7A88BD29AECFQ27304386-91C5B929-D861-4B06-995F-DFD92C1B6882Q27312275-606792F1-201F-4EC4-8D81-DF3D501DD64CQ27321704-B92AB17F-CC5E-4BD1-8214-613F7C6AE41EQ27323759-B807A9BA-729B-4AA3-93A9-6FFBCB709288Q27347956-A870A9BB-0CFF-41FE-A47E-AA68C4038702Q27666573-D43F29C8-68FA-42A4-9F10-18A48BD8C66A
P2860
description
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2010
@ast
im April 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: April 2010)
@en
wetenschappelijk artikel (gepubliceerd in 2010-04)
@nl
наукова стаття, опублікована у квітні 2010
@uk
مقالة علمية (نشرت في أبريل 2010)
@ar
name
PARP inhibition: PARP1 and beyond
@ast
PARP inhibition: PARP1 and beyond
@en
type
label
PARP inhibition: PARP1 and beyond
@ast
PARP inhibition: PARP1 and beyond
@en
prefLabel
PARP inhibition: PARP1 and beyond
@ast
PARP inhibition: PARP1 and beyond
@en
P2093
P2860
P3181
P356
P1476
PARP inhibition: PARP1 and beyond
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/NRC2812
P407
P577
2010-04-01T00:00:00Z
P5875
P6179
1040684149